Moderna, Inc. (MRNA)
NASDAQ · Healthcare · Biotechnology
Profile
Moderna, Inc.
- Exchange
- NASDAQ
- Ticker
- MRNA
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Key facts
Moderna, Inc.: key facts
- Moderna, Inc. (NASDAQ: MRNA) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Moderna, Inc. reported revenue of $1.9B and net income of -$2.8B.
- Revenue fell 42.5% a year over the last 4 fiscal years.
- Free cash flow was positive in 2 of the last 5 fiscal years.
- Net income was positive in 2 of the last 5 fiscal years.
- Over the last twelve months, revenue was $2.2B and net income was -$3.2B.
MonkScore
Moderna, Inc.'s MonkScore
MonkScore
MonkScore range: 50–60
as of October 2026
Sector rank: 330 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth50–60
- Profitability50–60
- Quality20–30
- Market Conviction90–100
- Safety90–100
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Moderna, Inc.'s annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $3.2B | $6.8B | $18.9B | $17.7B |
| Gross profit | -$280.0M | $1.1B | $1.7B | $2.2B | $13.5B | $15.1B |
| Operating income | -$3.3B | -$3.1B | -$3.9B | -$4.2B | $9.4B | $13.3B |
| Net income | -$3.2B | -$2.8B | -$3.6B | -$4.7B | $8.4B | $12.2B |
| Operating cash flow | -$1.1B | -$1.9B | -$3.0B | -$3.1B | $5.0B | $13.6B |
| Capital expenditure | -$171.0M | -$192.0M | -$1.1B | -$707.0M | -$400.0M | -$284.0M |
| Free cash flow | -$1.2B | -$2.1B | -$4.1B | -$3.8B | $4.6B | $13.3B |
| Total debt | $1.3B | $1.9B | $747.0M | $1.2B | $1.2B | $916.0M |
| Cash | $1.7B | $2.6B | $1.9B | $2.9B | $3.2B | $6.8B |
Revenue growth a year
- 1-year
- -39.2%
- 3-year
- -53.1%
- 4-year
- -42.5%
Compound growth between fiscal years.
Peers
Similar companies
- Dianthus Therapeutics, Inc.NASDAQ:DNTHMonkScore range: 50–60
- Ligand Pharmaceuticals IncorporatedNASDAQ:LGNDMonkScore range: 50–60
- Legend Biotech CorporationNASDAQ:LEGNMonkScore range: 50–60
- Incyte CorporationNASDAQ:INCYMonkScore range: 50–60
- Vericel CorporationNASDAQ:VCELMonkScore range: 50–60
- Jazz Pharmaceuticals plcNASDAQ:JAZZMonkScore range: 60–70
- Harmony Biosciences Holdings, Inc.NASDAQ:HRMYMonkScore range: 60–70
- Iovance Biotherapeutics, Inc.NASDAQ:IOVAMonkScore range: 60–70
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.